Century Therapeutics, Inc.

IPSC Healthcare Biotechnology

Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.37 0.13 −8.67%
Market cap
$271.6M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
4/9
Altman Z
−3.39
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.28 10.25 5.97 6.25
Net Debt/EBITDA
3.51 6.45 6.71 3.96
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.10) (0.13) (0.18) (0.30)
Book value per Share
1.13 1.37 1.84 2.04
Free Cash Flow
(20.47) (25.85) (15.94) (25.78)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates